{
  "id": 13145465,
  "title": "FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts",
  "url": "https://urgent.news/2026/10/09/fda-review-docs-spark-revolution-sell-off-zealand-diabetes-data",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-09T15:18:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/rasonque-fda-zealand-tukysa-ultragenyx-tcgx-china/832492/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a much-needed cash infusion and TCGX started a China-focused fund.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}